CDMO– tag –
-
Cell and Gene Therapy GMP Services Market Forecast to Reach $5.88 Billion by 2030, Growing at 18.9% CAGR
The Business Research Company Global Overview The Business Research Company released a report forecasting the GMP services market for cell and gene therapy to reach $2.95 billion in 2026 and expand to $5.88 billion by 2030, exhibiting an... -
Cellipont Bioservices Supports Six Cell Therapy Programs Towards 2026 IND Filings, Highlighting CDMO Market Growth
Cellipont Bioservices (via Contract Pharma news) USA Overview Texas-based cell therapy CDMO Cellipont Bioservices announced it is supporting six client projects anticipated to reach Investigational New Drug (IND) submission in 2026. Thei... -
Viral Vector Packaging Services Market Signals Rapid Growth Driven by Gene Therapy Commercialization and Increased Biomanufacturing Investment
openPR.com USA Overview This article provides an overview of a market research report from openPR.com. The global viral vector packaging services market is experiencing rapid growth, driven by advancing gene therapy commercialization and... -
CDMO Signal Ranks Viral Vector CDMOs: Thermo Fisher Scientific, AGC Biologics, and Takeda Lead Top Tier
CDMO Signal USA Overview CDMO Signal released its latest ranking of viral vector CDMOs, including AAV, lentiviral, and adenoviral modalities. Thermo Fisher Scientific, AGC Biologics, and Takeda secured top positions in the overall Signal... -
Lonza Appoints Samanta Cimitan as Chief Commercial Officer (CCO) to Enhance Customer Engagement and Accelerate Growth
Fierce Pharma Switzerland Overview Lonza announced the appointment of Samanta Cimitan as its new Chief Commercial Officer (CCO), effective January 1, 2027. This strategic move aims to integrate Lonza's strategic enterprise account manage... -
AGC Biologics Highlights Strengths as Global CDMO Partner for Biologics and Advanced Therapies
The Economy Global Overview AGC Biologics is recognized as a global biopharmaceutical CDMO providing development and manufacturing services across a wide range of advanced modalities, including biologics, plasmid DNA, mRNA, viral vectors... -
ProBio Establishes Cell and Gene Therapy CDMO Center of Excellence in Hopewell, New Jersey, Specializing in Plasmid DNA and Viral Vector Manufacturing
ProBio USA Overview ProBio has opened a Cell and Gene Therapy Center of Excellence in Hopewell, New Jersey, focusing on the development and GMP manufacturing of plasmid DNA and viral vectors. This new facility is designed to meet stringe... -
WuXi Biologics Reports 18.4% H1 2026 Revenue Growth and 300 IND Application Capacity Annually, Driven by Low-Cost Strategy
Seeking Alpha China Overview WuXi Biologics announced robust financial results for H1 2026, with revenue increasing by 18.4%, primarily driven by demand for investigational drugs and multi-specific antibodies. The company has expanded it... -
Celularity and MuseCell Innovations® Forge US Manufacturing Partnership, Projecting Over $300M in Purchases for Dezawa MuseCell® Platform
Celularity (Press Release) USA Overview Celularity Inc. announced a US manufacturing collaboration with MuseCell Innovations®, with Celularity's Florham Park, NJ facility set to produce Dezawa MuseCells® and related products. This partne... -
CDMOs Overcome Multispecific Manufacturing Challenges with Continuous Bioprocessing and Catalent’s GPEx® Lightning Platform
BioSpace Unknown Overview Contract Development and Manufacturing Organizations (CDMOs) confront complex challenges in cell line development, analytical characterization, and downstream purification for multispecific molecules. To overcom...
